Researchers report that rentosertib, an AI-discovered TNIK inhibitor, showed promising safety and potential to improve lung function in patients with idiopathic pulmonary fibrosis in a 12-week phase 2a clinical trial.
The highest dose group demonstrated a trend toward increased forced vital capacity, especially among patients not receiving standard antifibrotic therapy, supporting further clinical investigation.